摘要
目的:研究集采政策对辽宁省头孢菌素使用情况的影响。方法:提取辽宁省公立医疗机构2018年1月~2021年9月头孢使用数据,并采用Mann-Whitney U统计学方法以及间断时间序列模型分析集采政策对其产生的影响。结果:集采实施后,辽宁省公立医疗机构各代头孢菌素使用频度并未增加,并在疫情的影响下有所下降;第三代头孢菌素使用频度占比在疫情爆发后以及集采实施后均保持稳定,但是第四代头孢菌素的使用频度占比在集采执行当月即显著提高了0.30%(P<0.01);非集采中选品规头孢菌素的使用频度在集采实施后大幅下降。结论:头孢菌素使用频度在集采政策实施后未出现异常增长现象。但是仍需建立完善且有效的集采中选抗菌药物使用监测体系,对同类品种之间替换使用进行临床综合评价,并建议对ICU等对原研药有较大需求的危重症特殊科室放开集采药品用量考核标准。
Objective To study the influence of national centralized drug procurement(NCDP) policy on the use of cephalosporins in Liaoning Province. Methods Procurement data of cephalosporins in public health institutions in Liaoning Province from January 2018 to September 2021 were obtained, and analyzed with Mann-whitneyUtest and interrupted time series analysis method. Results There was no increase in DDDs of cephalosporins in each generation after the implementation of policy, and it even showed a decrease because of the outbreak of COVID-19 pandemic. No significant level or slope change was found in the DDDs proportion of third generation cephalosporins after the pandemic and the policy, while a significant increase for the immediate change in DDDs proportion of the fourth generation cephalosporins was detected after the policy(P< 0. 01). There was a significant decrease in DDDs of cephalosporins which was not on the NCDP List after the implementation of policy. Conclusion DDDs of cephalosporins didn’t increase abnormally after the implementation of the policy, while a robust monitoring system is still needed. And clinical comprehensive evaluation should be carried out for the substitutions of drugs in the same class. The performance appraisal standards for the coverage of drugs on the NCDP List should be relaxed in ICU and other special departments with a large demand for original branded drugs.
作者
宋雪
黄哲
杨坚
蒯丽萍
徐冬艳
谢宇
Song Xue(School of Business Administration,Shenyang Pharmaceutical University,Shenyang,P.R.China)
出处
《中国卫生事业管理》
北大核心
2023年第2期128-131,152,共5页
Chinese Health Service Management
基金
辽宁“百千万人才工程”培养经费资助“药品连续制造的质量考量和监管策略研究”(110)
2020年辽宁省高等学校创新人才支持计划“提升辽宁省公共卫生突发事件的应急管理效能研究”(02)
沈阳市2020年度科技人才项目“公共卫生重大风险防范机制及应对策略研究”(RC200498)
辽宁省自然科学基金资助项目“辽宁省制药企业绿色技术创新实现路径研究”(2020-MS-194)
沈阳药科大学2021年度工商管理学院学科建设课题资助“基于区块链技术的药品企业监管风险分析模型与应用研究”(2021-sygsxk-02)。
